

# 해외 바이오의약품 임상 현황 ('22년 11월 4주)

한국바이오의약품협회, 2022.11.29.

※ ClinicalTrials.gov에 등록된 국가별 바이오의약품 임상시험 목록(병용요법 포함)을 한국바이오의약품협회에서 주간 업데이트하여 제공합니다.  
 NCT number를 클릭하시면 세부 정보 페이지로 연결됩니다.  
 - 출처: ClinicalTrials.gov  
 - 모니터링 기간: 2022.11.21. ~ 2022.11.27.  
 - 주간 업데이트 제공국가 : 미국, 유럽(영국, 프랑스, 독일), 중국, 일본

## ○ 미국 6건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
<a href="#">NCT05620771</a>	Therasphere and Systemic Therapy for Patients With Hepatocellular Carcinoma That is High-risk	Drug: Atezolizumab and Bevacizumab Drug: Y90 + TKI	Northwestern University National Cancer Institute (NCI)	Phase 2	<a href="#">https://clinicaltrials.gov/ct2/show/study/NCT05620771</a>
<a href="#">NCT05526989</a>	Study of the Combination Dostarlimab With Niraparib In Patients With Penile Carcinoma	Drug: Dostarlimab Drug: Niraparib	H. Lee Moffitt Cancer Center and Research Institute GlaxoSmithKline	Phase 2	<a href="#">https://clinicaltrials.gov/ct2/show/study/NCT05526989</a>
<a href="#">NCT05242965</a>	A Multiple Antigen Vaccine (STEMVAC) for the Treatment of Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer	Biological: CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine Biological: Sargramostim	University of Washington United States Department of Defense	Phase 2	<a href="#">https://clinicaltrials.gov/ct2/show/study/NCT05242965</a>
<a href="#">NCT05161533</a>	Hypofractionated Radiation Therapy After Durvalumab and Chemotherapy for the Treatment of Stage IV Extensive Stage Small Cell Lung Cancer, CASPIAN-RT Trial	Drug: Carboplatin Drug: Cisplatin Biological: Durvalumab Drug: Etoposide Radiation: Hypofractionated Radiation Therapy Other: Quality-of-Life Assessment Other: Questionnaire Administration	University of Washington AstraZeneca	Phase 2	<a href="#">https://clinicaltrials.gov/ct2/show/study/NCT05161533</a>
<a href="#">NCT05574335</a>	Siplizumab in T1DM	Drug: Siplizumab	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 1 Phase 2	<a href="#">https://clinicaltrials.gov/ct2/show/study/NCT05574335</a>
<a href="#">NCT05556096</a>	Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis	Combination Product: ALXN1720 Combination Product: Placebo	Alexion Pharmaceuticals	Phase 3	<a href="#">https://clinicaltrials.gov/ct2/show/study/NCT05556096</a>

## ○ 영국 2건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
<a href="#">NCT05394116</a>	The Examination of Safety and Efficacy of Garetosmab Versus Placebo Administered Intravenously (IV) in Adult Participants With Fibrodysplasia Ossificans Progressiva (FOP)	Drug: Garetosmab Drug: Placebo	Regeneron Pharmaceuticals	Phase 3	<a href="#">https://clinicaltrials.gov/ct2/show/study/NCT05394116</a>
<a href="#">NCT05556096</a>	Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis	Combination Product: ALXN1720 Combination Product: Placebo	Alexion Pharmaceuticals	Phase 3	<a href="#">https://clinicaltrials.gov/ct2/show/study/NCT05556096</a>

## ○ 프랑스 3건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
<a href="#">NCT05605496</a>	NP137 Clinical and Biological Activities Assessment in Patients With Advanced/Metastatic Solid Tumors Treated by Standard Anti PD-1/PD-L1 Immunotherapies	Drug: NP137 Drug: anti-PD-1/PD-L1	Centre Leon Berard NETRIS Pharma	Phase 2	<a href="#">https://clinicaltrials.gov/ct2/show/study/NCT05605496</a>
<a href="#">NCT05468320</a>	Caplacizumab and Immunosuppressive Therapy Without Firstline Therapeutic Plasma Exchange in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura	Drug: Caplacizumab Drug: Corticosteroids Biological: anti-CD20 antibody	Sanofi	Phase 3	<a href="#">https://clinicaltrials.gov/ct2/show/study/NCT05468320</a>
<a href="#">NCT05556096</a>	Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis	Combination Product: ALXN1720 Combination Product: Placebo	Alexion Pharmaceuticals	Phase 3	<a href="#">https://clinicaltrials.gov/ct2/show/study/NCT05556096</a>

# 해외 바이오의약품 임상 현황 ('22년 11월 4주)

한국바이오의약품협회, 2022.11.29.

## ○ 독일 2건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
<a href="#">NCT05468320</a>	Caplacizumab and Immunosuppressive Therapy Without Firstline Therapeutic Plasma Exchange in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura	Drug: Caplacizumab Drug: Corticosteroids Biological: anti-CD20 antibody	Sanofi	Phase 3	<a href="#">https://clinicaltrials.gov/ct2/show/study/NCT05468320</a>
<a href="#">NCT05556096</a>	Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis	Combination Product: ALXN1720 Combination Product: Placebo	Alexion Pharmaceuticals	Phase 3	<a href="#">https://clinicaltrials.gov/ct2/show/study/NCT05556096</a>

## ○ 중국 4건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
<a href="#">NCT05618327</a>	Phase I Clinical Study of JS203 in Patients With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma	Drug: JS203 for Injection	Shanghai Junshi Bioscience Co., Ltd.	Phase 1	<a href="#">https://clinicaltrials.gov/ct2/show/study/NCT05618327</a>
<a href="#">NCT05606913</a>	A Study of IBI362 in Participants With Type 2 Diabetes	Drug: dulaglutide Drug: IBI362	Innovent Biologics (Suzhou) Co. Ltd.	Phase 3	<a href="#">https://clinicaltrials.gov/ct2/show/study/NCT05606913</a>
<a href="#">NCT05596747</a>	A Study of LY3209590 in Chinese Participants With Type 2 Diabetes Mellitus	Drug: LY3209590 Drug: Insulin Glargine	Eli Lilly and Company	Phase 1	<a href="#">https://clinicaltrials.gov/ct2/show/study/NCT05596747</a>
<a href="#">NCT05556096</a>	Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis	Combination Product: ALXN1720 Combination Product: Placebo	Alexion Pharmaceuticals	Phase 3	<a href="#">https://clinicaltrials.gov/ct2/show/study/NCT05556096</a>

## ○ 일본 1건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
<a href="#">NCT05556096</a>	Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis	Combination Product: ALXN1720 Combination Product: Placebo	Alexion Pharmaceuticals	Phase 3	<a href="#">https://clinicaltrials.gov/ct2/show/study/NCT05556096</a>